Literature DB >> 16176881

Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex.

Lisbeth Birk Møller1, Marianne Paulsen, Richard Koch, Rex Moats, Per Guldberg, Flemming Güttler.   

Abstract

It remains a question why some patients with phenylketonuria (PKU) have high IQ and low brain phenylalanine (Phe) concentrations in spite of high blood Phe levels. One possible explanation for the low brain Phe concentrations in these patients would be a reduced transport of Phe across the blood-brain barrier. The 4F2hc/LAT1 complex has been suggested to be the most important molecular component responsible for this transport. To test the hypothesis that structural variant(s) in the genes encoding 4F2hc and LAT1 might result in a complex with reduced affinity for Phe, we have screened the two genes for sequence variants in a group of 13 PKU patients with a low ratio of brain to blood Phe concentrations. Several common sequence variants were identified, but none of these is predicted to affect the resulting protein product. Our data suggest that individual vulnerability to Phe in patients with PKU is not due to structural variants in the 4F2hc/LAT1 complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16176881     DOI: 10.1016/j.ymgme.2005.07.031

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

1.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

2.  Can untreated PKU patients escape from intellectual disability? A systematic review.

Authors:  Danique van Vliet; Annemiek M J van Wegberg; Kirsten Ahring; Miroslaw Bik-Multanowski; Nenad Blau; Fatma D Bulut; Kari Casas; Bozena Didycz; Maja Djordjevic; Antonio Federico; François Feillet; Maria Gizewska; Gwendolyn Gramer; Jozef L Hertecant; Carla E M Hollak; Jens V Jørgensen; Daniela Karall; Yuval Landau; Vincenzo Leuzzi; Per Mathisen; Kathryn Moseley; Neslihan Ö Mungan; Francesca Nardecchia; Katrin Õunap; Kimberly K Powell; Radha Ramachandran; Frank Rutsch; Aria Setoodeh; Maja Stojiljkovic; Fritz K Trefz; Natalia Usurelu; Callum Wilson; Clara D van Karnebeek; William B Hanley; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2018-08-29       Impact factor: 4.123

3.  Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?

Authors:  Danique van Vliet; Annemiek M J van Wegberg; Kirsten Ahring; Miroslaw Bik-Multanowski; Kari Casas; Bozena Didycz; Maja Djordjevic; Jozef L Hertecant; Vincenzo Leuzzi; Per Mathisen; Francesca Nardecchia; Kimberly K Powell; Frank Rutsch; Maja Stojiljkovic; Fritz K Trefz; Natalia Usurelu; Callum Wilson; Clara D van Karnebeek; William B Hanley; Francjan J van Spronsen
Journal:  Nutrients       Date:  2019-10-25       Impact factor: 5.717

4.  The rs113883650 variant of SLC7A5 (LAT1) gene may alter brain phenylalanine content in PKU.

Authors:  Miroslaw Bik-Multanowski; Kinga Bik-Multanowska; Iwona Betka; Anna Madetko-Talowska
Journal:  Mol Genet Metab Rep       Date:  2021-03-31

5.  Optimising amino acid absorption: essential to improve nitrogen balance and metabolic control in phenylketonuria.

Authors:  Anita MacDonald; Rani H Singh; Júlio César Rocha; Francjan J van Spronsen
Journal:  Nutr Res Rev       Date:  2018-10-04       Impact factor: 7.800

Review 6.  Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment.

Authors:  Jingshun Zhang; Ying Xu; Dandan Li; Lulu Fu; Xueying Zhang; Yigang Bao; Lianwen Zheng
Journal:  Front Chem       Date:  2020-10-20       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.